Overview

A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
SSG XX is a phase II trial for high-risk soft tissue sarcomas (STS) of the extremities and trunk wall. Prognostic factors (histopathological markers) are used to identify high-risk tumors. SSG XX will evaluate chemo- and radiotherapy given adjuvantly to these patients. In a specified group of patients also preoperatively given therapy will be studied.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborator:
Scandinavian Sarcoma Group
Treatments:
Doxorubicin
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin